搜尋結果
VAXIGRIP TETRA is indicated for the prevention of influenza disease caused by the two influenza. virus subtypes and the two influenza B virus types contained in the vaccine for: active immunisation of adults, including pregnant women, and children from 6 months of age. and older,
2023 Profile of Sanofi's Vaccines Business Unit References World Health Organization (2019) Immunization Facts in Pictures. Accessed October 2022 MAT-GLB-2200131 v2 – 12/2022 Page updated December 2022 Continue to Your Health Follow us Back to ...
流感疫苗預約 – 2024 四價流感疫苗 (Vaxigrip Tetra) 藥廠：法國 Sanofi. 接種針數：共1針. 適合人群：滿6個月或以上人士，9歲以上：接種 1 針 ， 9歲以下且從未注射過流感疫苗：接種 2 針 (相隔至少1個月) 疫苗成分：四種流感病毒. 2023/24 季度，疫苗可預防疾病科學委員會建議的四價流感疫苗成分包括以下 4 種流感病毒（2種類甲型及 2種類乙型流感病毒）： A/Victoria/4897/2022 (H1N1)pdm09-like strain (A/Victoria/4897/2022, IVR-238) A/Darwin/9/2021 (H3N2)-like strain (A/Darwin/6/2021, IVR-227)
2018年3月8日 · Vaxigrip Tetra ® (Sanofi Pasteur) is a novel four-strain influenza vaccine belonging to the Vaxigrip ® family of influenza vaccines []. It is a quadrivalent split-virion inactivated influenza vaccine containing the purified HA and NA antigens from the four influenza virus strains recommended by the WHO [ 79 ].
- Emanuele Montomoli, Alessandro Torelli, Ilaria Manini, Elena Gianchecchi
- 10.3390/vaccines6010014
- 2018
- Vaccines (Basel). 2018 Mar; 6(1): 14.
This quadrivalent formulation of Vaxigrip contains two A and two B influenza strains (VaxigripTetra), and has a similar immunogenicity and safety profile to the trivalent formulation while offering broader protection due to the addition of the second influenza B strain.
- Margaret Haugh, Viviane Gresset-Bourgeois, Bérengère Macabeo, Anne Woods, Sandrine I. Samson
- 2017
Abstract. VaxigripTetra™ (IIV4; Sanofi Pasteur) is a quadrivalent split-virion influenza vaccine approved in Europe in 2016 for individuals ≥ 3 years of age. IIV4 builds on the well-established record of the trivalent split-virion influenza vaccine (Vaxigrip®).
衛生署為求接種安全，宣布暫時停止法國賽諾菲廠牌之流感疫苗接種. Facebook Line 列印. 針對外電報導，以色列傳出四名疑似接種流感疫苗後死亡事件，雖然以色列政府表示，該事件目前尚未證明與流感疫苗接種有直接相關，但衛生署基於民眾接種安全之審慎考量，宣布暫時停止已供應全國各縣市之法國賽諾菲（Sanofi Pasteur）藥廠（原Aventis藥廠）的流感疫苗接種，同時已請各縣市衛生局立即轉知轄區所有接種單位，至於其他廠牌之流感疫苗接種作業仍持續進行。 衛生署疾病管制局表示，該局已儘速透過駐外單位及國內賽諾菲安萬特股份有限公司，緊急向以色列追查事件發生原委，同時向原廠追查相關流感疫苗供貨及使用情形，將會儘速釐清確認該廠牌流感疫苗之品質、安全無虞後，再回復其疫苗供應及接種作業。
